BPS 804

Drug Profile

BPS 804

Alternative Names: BPS-804

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MorphoSys; Novartis
  • Developer Mereo BioPharma; Novartis
  • Class Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action SOST protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteogenesis imperfecta
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteogenesis imperfecta
  • Discontinued Hypophosphatasia; Postmenopausal osteoporosis

Most Recent Events

  • 13 Nov 2017 BPS 804 receives Priority Medicine (PRIME) status for Osteogenesis imperfecta in European Union
  • 09 Oct 2017 Mereo BioPharma initiates enrolment in the METEOROID trial for Osteogenesis imperfecta in USA (NCT03216486)
  • 12 Jul 2017 Mereo BioPharma plans the phase II METEOROID trial in Osteogenesis imperfecta in USA (NCT03216486)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top